Close

Home Page

Company Database

Licensing Deals

Investors

Database provided by

Featured company

Shanghai Hansoh BioMedical Co., Ltd. - Hansoh pharmaceutical
Shanghai Hansoh BioMedical Co., Ltd. - Hansoh pharmaceutical

Partners



Fc Protein and Glycoengineered Antibodies Market
By: PR Newswire Association LLC. - 05 Mar 2014Back to overview list

Research and Markets

DUBLIN, March 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from both large and small pharmaceutical companies. Developed through introduction of modifications in monoclonal antibodies, the aim is to develop antibodies with improved efficacy.

Research done in the last decade to develop engineered antibodies has yielded a rich knowledge base on how to develop and market these next generation antibodies. These therapeutic antibodies seem to be more promising, with improved properties when compared to their ancestors. There are several molecules in phase II / III clinical trials and a few waiting for approvals. In addition, a large number of molecules are also in pre-clinical trials and are expected to progress through various stages of drug development over the next ten years.

The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline.

For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are:

  • Fc Glycoengineering (referred to as Glycoengineering' in the report)
  • Fc Protein engineering

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. INTRODUCTION

3. ENGINEERED ANTIBODIES: OVERVIEW AND BACKGROUND

4. GLYCOENGINEERED ANTIBODIES MARKET, 2012 - 2023

5. Fc PROTEIN ENGINEERED ANTIBODIES MARKET, 2013 - 2023

6. TECHNOLOGICAL PLATFORMS FOR ENGINEERED ANTIBODIES

7. PROFILES OF LEADING COMPANIES

8. SWOT ANALYSIS

9. CONCLUSIONS

10. APPENDIX 1: TABLES

11. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS


Companies Mentioned:

  • ABN AMRO Capital
  • AVID Bioservices
  • Absolute Antibody
  • Accurus Biosciences
  • Affitech A/S
  • Allos Therapeutics
  • Amgen
  • Andromeda Biotech
  • Applied Molecular Evolution (AME)
  • Astra Zeneca
  • BioMedinvest
  • BioWa
  • BioXcellence
  • BioXpress Therapeutics
  • Bioceros
  • Biocon
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • CSL
  • Celltrion
  • Centocor Ortho Biotech
  • Cephalon
  • ChemoCentryx
  • Chugai Pharmaceuticals
  • Deutsche Venture Capital
  • Diamyd Medical
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Eureka Therapeutics
  • Five Prime Therapeutics
  • GSK
  • Genentech
  • Gilde Investment Management
  • Global Life Science Ventures
  • Glycart
  • Glycode
  • Glycotope
  • Green Cross Corporation
  • Greenovation
  • Halozyme Therapeutics
  • Hanwha Chemical
  • Human Genome Sciences
  • ISU Abxis
  • Ildong Pharmaceuticals
  • ImmunGene
  • Inhibrx
  • InvivoGen
  • KaloBios
  • Kyowa Hakko Kirin
  • Laboratoire français du Fractionnement et des Biotechnologies (LFB)
  • Life Science Pharmaceuticals
  • Lonza
  • MacroGenics
  • MedImmune
  • Meiji Seika Pharma
  • Mentrik Biotech
  • Merck-GlycoFi
  • Micromet
  • MilleGen
  • Minapharm Pharmaceuticals
  • Morphosys
  • Mylan
  • NKT Therapeutics
  • Nippon Kayaku
  • Nippon Shinyaku
  • Novartis
  • Novartis Venture Fund
  • Ortho-McNeil Janssen Pharmaceutical
  • PDL Biopharma
  • Pfizer
  • Pikamab
  • Pinnacle Oncology Hematology
  • PlantForm Corporation
  • ProStrakan
  • Quester Capital Management
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Schnell Biopharma
  • Seattle Genetics
  • Servier
  • Shanghai CP Guojian
  • SiaMedExpress
  • Sorrento Therapeutics
  • Synthon-Biolex
  • TG Therapeutics
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals
  • Trubion
  • Vivalis
  • Watson Pharmaceuticals
  • WuXi AppTec
  • Xencor
  • Zymeworks
  • arGEN-X
  • biOasis Technologies
  • rEVO Biologic

For more information visit http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

Related companies:RBC Capital Market | KeyBanc Capital Markets
Copyright 2014 PR Newswire. All Rights Reserved Back to overview list